The estimated Net Worth of Garo H Armen is at least $14.5 Million dollars as of 15 February 2024. Garo Armen owns over 500,000 units of Agenus Inc stock worth over $3,530,465 and over the last 21 years he sold AGEN stock worth over $1,007,854. In addition, he makes $9,937,040 as Chairman of the Board, Chief Executive Officer und Co-Founder at Agenus Inc.
Garo has made over 8 trades of the Agenus Inc stock since 2011, according to the Form 4 filled with the SEC. Most recently he bought 500,000 units of AGEN stock worth $325,000 on 15 February 2024.
The largest trade he's ever made was buying 2,150,976 units of Agenus Inc stock on 16 August 2011 worth over $1,096,998. On average, Garo trades about 16,156 units every 21 days since 2004. As of 15 February 2024 he still owns at least 625,969 units of Agenus Inc stock.
You can see the complete history of Garo Armen stock trades at the bottom of the page.
Dr. Garo H. Armen Ph.D. serves as Chairman of the Board, Chief Executive Officer, Co-Founder of the Company. Dr. Armen is Chairman and Chief Executive Officer of Agenus Inc., which he co-founded in 1994. Dr. Armen brings to our Board a deep historical and practical knowledge of the business of the Company and its technologies, as well as years of expertise in the financial and biopharmaceutical arenas. From mid-2002 through 2004, he was Chairman of the Board of Directors for the biopharmaceutical company Elan Corporation, plc which he helped restructure. Dr. Armen currently serves as non-executive Chairman of the Board of Directors of Protagenic Therapeutics, Inc., a publicly held biotechnology company. Dr. Armen is also the founder and Chairman of the Children of Armenia Fund, a philanthropic organization established in 2000 that is dedicated to the positive development of the children and youth of rural Armenia. He holds a Ph.D. degree in physical organic chemistry from the City University of New York.
As the Chairman of the Board, Chief Executive Officer und Co-Founder of Agenus Inc, the total compensation of Garo Armen at Agenus Inc is $9,937,040. There are no executives at Agenus Inc getting paid more.
Garo Armen is 66, he's been the Chairman of the Board, Chief Executive Officer und Co-Founder of Agenus Inc since 1994. There are 3 older and 10 younger executives at Agenus Inc. The oldest executive at Agenus Inc is Wadih Jordan, 85, who is the Independent Director.
Garo's mailing address filed with the SEC is C/O AGENUS INC., 3 FORBES ROAD, LEXINGTON, MA, 02421.
Over the last 23 years, insiders at Agenus Inc have traded over $24,466,328 worth of Agenus Inc stock and bought 13,248,226 units worth $63,837,873 . The most active insiders traders include Associates Gp Llcqvt Fund V..., Noubar Afeyan und Corp Incyte. On average, Agenus Inc executives and independent directors trade stock every 99 days with the average trade being worth of $2,230,885. The most recent stock trade was executed by Garo H Armen on 15 February 2024, trading 500,000 units of AGEN stock currently worth $325,000.
agenus is an immunology company discovering and developing novel checkpoint modulators, vaccines and adjuvants to treat cancer and other diseases. we are a dedicated group of scientists, researchers, biotechnologists, physicians, and businesspeople working together toward one goal: to discover and develop therapies that can unleash the innate power of the body’s immune system to treat and potentially cure hard-to-treat cancers and other diseases. our product candidates are designed to work by educating and activating the body’s immune system for a precise and potent attack on cancer. our strategy is to help unlock the potential of one of the most exciting breakthrough areas in cancer treatment in decades, and to develop single agent and combination immune-oncology therapies that can help save lives. our approaches are driven by three platform technologies, including: • our antibody platforms, including our proprietary retrocyte display™ and secant® technologies, and our antibody
Agenus Inc executives and other stock owners filed with the SEC include: